Effect of multidose cilostazol on pharmacokinetic and lipid profile of atorvastatin in male Wistar rats

Journal of Pharmacy and Pharmacology

Volumn 64, Issue 11, 2012, Pages 1638-1645

  Vats, Rahul ^a   Varanasi, Kanthikiran V S ^b   Arla, Rambabu ^b   Veeraraghavan, Sridhar ^b   Rajak, Shraddha ^b   Murthy, Aditya Narasimha ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

^b Glenmark Pharmaceuticals Limited   (India)

Author keywords

atorvastatin; cilostazol; lipid profile; pharmacokinetic and pharmacodynamic interaction

Indexed keywords

ATORVASTATIN; CHOLESTEROL; CILOSTAZOL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; DRUG METABOLISM; DRUG PENETRATION; EVENING DOSAGE; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NONHUMAN; RAT; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; WISTAR RAT;

ANIMALS; CHOLESTEROL; CHOLESTEROL, LDL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG INTERACTIONS; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MICROSOMES, LIVER; PYRROLES; RATS; RATS, WISTAR; TANDEM MASS SPECTROMETRY; TETRAZOLES; TRIGLYCERIDES; VASODILATOR AGENTS;

EID: 84867577328     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2012.01542.x     Document Type: Article

References (38)

1. HIV drug-drug interactions. New York State Department of Health AIDS Institute. http://www.hivguidelines.org/wp-content/uploads/a-hiv-drug-drug- interactions-04-14-2010.pdf accessed on 8 April 2012.
2. Zhang L, et al,. Scientific perspectives on drug transporters and their role in drug interactions. Mol Pharm 2006; 3: 62-69.
3. Schrör K,. The pharmacology of cilostazol. Diabetes Obes Metab 2002; 4: S14-S19.
4. Ji X, Hou M,. Novel agents for anti-platelet therapy. J Hematol Oncol 2011; 4: 44.
5. Hiatt WR,. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001; 344: 1608-1621.
6. Liu Y, et al,. Phosphodiesterases as targets for intermittent claudication. Handb Exp Pharmacol 2011; 204: 211-236.
7. Chapman TM, Goa KL,. Cilostazol: a review of its use in intermittent claudication. Am J Cardiovasc Drugs 2003; 3: 117-138.
8. Elam MB, et al,. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol 1998; 18: 1942-1947.
9. Abbas R, et al,. In vitro metabolism and interaction of cilostazol with human hepatic cytochrome P450 isoforms. Hum Exp Toxicol 2000; 19: 178-184.
10. Akiyama H, et al,. The absorption, distribution and excretion of a new antithrombotic and vasodilating agent, cilostazol, in rat, rabbit, dog and man. Arzneimittelforschung 1985; 35: 1124-1132.
11. Toyobuku H, et al,. Limited influence of P-glycoprotein on small-intestinal absorption of cilostazol, a high absorptive permeability drug. J Pharm Sci 2003; 92: 2249-2259.
12. Williams D, Feely J,. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002; 41: 343-370.
13. Bottorff MB,. Safety and statins: pharmacologic and clinical perspectives. Prev Med Manag Care 2004; 4: S30-S37.
14. Gibson DM, et al,. Absolute bioavailability or atorvastatin in man. Pharm Res 1997; 14: S253.
15. Lau YY, et al,. Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Drug Metab Dispos 2006; 34: 1175-1181.
16. Lennernas H,. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 2003; 42: 1141-1160.
17. Lins RL, et al,. Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients. Nephrol Dial Transplant 2003; 18: 967-976.
18. Black AE, et al,. Metabolism and excretion of atorvastatin between rats and dogs. Drug Metab Dispos 1999; 27: 916-923.
19. Le Couteur DG, et al,. Metabolism and excretion of [14C]-atorvastatin in patients with T-tube drainage. Proc Aust Soc Clin Exp Pharmacol Toxicol 1996; 3: 153.
20. Prueksaritanont T, et al,. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos 2002; 30: 505-512.
21. Hochman JH, et al,. Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin. Pharm Res 2004; 21: 1686-1691.
22. Boyd RA, et al,. Atorvastatin co-administration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol 2000; 40: 91-98.
23. Kantola T, et al,. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 1998; 64: 58-65.
24. Siedlik PH, et al,. Erythromycin co-administration increases plasma atorvastatin concentrations. J Clin Pharmacol 1999; 39: 501-504.
25. Lilja JJ, et al,. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin Pharmacol Ther 1999; 66: 118-127.
26. Bramer SL, et al,. Effect of multiple cilostazol doses on single dose lovastatin pharmacokinetics in healthy volunteers. Clin Pharmacokinet 1999; 37: 69-77.
27. Mitropoulos KA, Balasubramaniam S,. Cholesterol 7α-hydroxylase in rat liver microsomal preparations. Biochem J 1972; 128: 1-9.
28. Smith PK, et al,. Measurement of protein using bicinchoninic acid. Anal Biochem 1985; 150: 76-85.
29. Jia L, Wong H,. In vitro and in vivo assessment of cellular permeability and pharmacodynamics of S-nitrosylated captopril, a nitric oxide donor. Br J Pharmacol 2001; 134: 1697-1704.
30. Ma L, et al,. Development and validation of atorvastatin by LC-ESI-MS and application in bioequivalence research in healthy Chinese volunteers. Chromatographia 2007; 65: 737-741.
31. Food and Drug Administration (FDA). Guidance for Industry: Bio Analytical Method Validation. Rockvile: U.S. Department of Health and Human Services, 2001.
32. Gibson DM, et al,. Effect of age and gender on pharmacokinetics of atorvastatin in humans. J Clin Pharmacol 1996; 36: 242-246.
33. Whitfield LR, et al,. Effect of food on the pharmacodynamics and pharmacokinetics of atorvastatin, an inhibitor of HMG-CoA reductase. Eur J Drug Metab Pharmacokinet 2000; 25: 97-101.
34. Jacobsen W, et al,. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-coA reductase inhibitor atorvastatin. Drug Metab Dispos 2000; 28: 1369-1378.
35. Takara K, et al,. Expression profiles of drug-metabolizing enzyme CYP3A and drug efflux transporter multidrug resistance 1 subfamily m RNAS in small intestine. Drug Metab Dispos 2003; 31: 1235-1239.
36. Ravi PR, et al,. Effect of grapefruit juice and ritonavir on pharmacokinetics of lopinavir in wistar rats. Phytother Res 2012. doi: 10.1002/ptr.4593. [Epub ahead of print].
37. Christians U, et al,. Functional interactions between P-glycoprotein and CYP3A in drug metabolism. Expert Opin Drug Metab Toxicol 2005; 1: 641-654.
38. Maurya D, et al,. A Microwave induced solubility enhancement of poorly water soluble atorvastatin calcium. J Pharm Pharmacol 2010; 62: 1599-1606.